Search results
Results from the WOW.Com Content Network
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain . [ 2 ]
A transcutaneous electrical nerve stimulation (TENS or TNS) is a device that produces mild electric current to stimulate the nerves for therapeutic purposes.TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation, but the term is often used with a more restrictive intent, namely, to describe the kind of pulses produced by portable ...
The new drug price negotiations aim "to basically make drugs more affordable while also still allowing for profits to be made,” said Gretchen Jacobson, who researches Medicare issues at ...
Medicare has started its first-ever negotiations with drugmakers over the cost of 10 expensive medications, including Eliquis and Stelara. The prices charged in other countries are not a factor in ...
The Food and Drug Administration has granted approval for the next-generation anticlotting medication Eliquis, the regulator announced in a news release. The drug, administered in the form of a ...
It is commonly used by professional and performance athletes with acute pain and/or muscle tenderness as it is drug-free and non-invasive, thus avoiding testing and recovery issues. It is also used as a cosmetic treatment. [5]
Medicare’s historic drug price negotiation program has survived its first court challenge by a drugmaker. A federal district court judge in Delaware on Friday rejected AstraZeneca’s claims ...